Table 1.
Baseline characteristics of the study cohort (n = 74).
| Variable | n (% miss.) | Overall (n = 74) | Arm A (n = 36) | Arm B (n = 38) | p |
|---|---|---|---|---|---|
| Demographic variables | |||||
| Age (years) | 74 (0%) | 66 (58–72) | 66 (58–71) | 66 (56–73) | 0.871 |
| Female sex | 74 (0%) | 20 (27%) | 9 (25%) | 11 (29%) | 0.702 |
| ECOG ⩾1 point | 73 (1%) | 17 (23%) | 9 (25%) | 8 (22%) | 0.733 |
| Caucasian ethnicity | 74 (0%) | 74 (100%) | 36 (100%) | 38 (100%) | 0.999 |
| Cancer variables | |||||
| Stage IV at time of tumor diagnosis | 74 (0%) | 61 (82%) | 30 (83%) | 31 (82%) | 0.843 |
| Liver metastasis | 74 (0%) | 66 (89%) | 29 (81%) | 37 (97%) | 0.020 |
| Lung metastasis | 70 (5%) | 32 (46%) | 21 (62%) | 11 (31%) | 0.009 |
| KRAS mutation | 66 (11%) | 32 (48%) | 15 (44%) | 17 (53%) | 0.464 |
| IHC variables | |||||
| Origin of tissue: Primary tumor | 74 (0%) | 59 (80%) | 27 (75%) | 32 (84%) | 0.325 |
| CD31 (microvessels/HPF) | 73 (1%) | 11.2 (9.0–13.0) | 11.2 (9.2–13.0) | 11.1 (9.0–13.4) | 0.925 |
| PTEN IHC positive | 72 (3%) | 2 (3%) | 2 (6%) | 0 (0%) | 0.493 |
| uPAR IHC positive | 71 (4%) | 30 (42%) | 18 (50%) | 12 (34%) | 0.180 |
| NRP-1 expression | 72 (3%) | 2 (0–4) | 2 (0–4) | 2 (0–4) | 0.866 |
| αV-integrin expression | 67 (9%) | 4 (2–5) | 4 (2–5) | 4 (2–4) | 0.832 |
| CD98he IHC positive | 70 (5%) | 28 (40%) | 15 (44%) | 13 (36%) | 0.494 |
ECOG, Eastern Cooperative Oncology Group Performance Status; HPF, higher-power fields; IHC, immunohistochemistry; PTEN, phosphatase and tensin homolog; uPAR, urokinase receptor.